[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# Kyowa Kirin Co. Ltd.

Kyowa Kirin and Kura Oncology report positive combination data for KOMZIFTI in AML, while KOMZIFTI's first U.S. commercial sale triggers a $135M milestone payment.

### About Kyowa Kirin Co. Ltd.
Kyowa Kirin Co. Ltd. is a pharmaceutical company.  

### Insights
- Kyowa Kirin Co. Ltd. creators is up XX% from the previous week.
- Kyowa Kirin Co. Ltd. engagements is up XXX% from the previous week.
- Kyowa Kirin Co. Ltd. mentions is up XXX% from the previous week.

### Price: $
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$4151t/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$4151t/time-series/close.tsv)  
The price action is likely influenced by positive news regarding FDA approvals and new product launches, as indicated by social media discussions.  

1-Year High: $XXXXX on 2025-08-07  
1-Year Low: $XXXXXXXX on 2025-02-20  
  
  
### AltRank: XXX
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$4151t/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$4151t/time-series/alt_rank.tsv)  
Kyowa Kirin Co. Ltd. is currently AltRank #962 based on combined combined social and market metrics
Daily Average: XXXXX  
1-Year High: XXXXX on 2025-01-20  
1-Year Low: XXX on 2025-11-26  
  
  
### Galaxy Score: XX
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$4151t/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$4151t/time-series/galaxy_score.tsv)  
Current Value: XX  
Daily Average: XX  
1-Year High: XX on 2025-11-13  
1-Year Low: X on 2025-11-20  
  
  
### Engagements: XX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$4151t/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$4151t/time-series/interactions.tsv)  
Current Value: XX  
Daily Average: XXX  
X Week: XXX +378%  
X Month: XXXXXX +28%  
X Months: XXXXXXX +79%  
X Year: XXXXXXX +37%  
1-Year High: XXXXXX on 2025-09-09  
1-Year Low: X on 2024-12-15  

Engagements by network (24h):
X: XX

  
  
### Mentions: XX (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$4151t/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$4151t/time-series/posts_active.tsv)  
Current Value: XX  
Daily Average: X  
X Week: XX +110%  
X Month: XX +2.20%  
X Months: XXX +38%  
X Year: XXX +117%  
1-Year High: XX on 2025-09-09  
1-Year Low: X on 2024-12-13  

Mentions by network (24h):
X: XX

  
  
### Creators: X (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$4151t/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$4151t/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning Kyowa Kirin Co. Ltd. in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X  
X Week: XX +80%  
X Month: XX no change  
X Months: XXX +55%  
X Year: XXX +47%  
1-Year High: XX on 2025-09-09  
1-Year Low: X on 2024-12-13  

The most influential creators that mention Kyowa Kirin Co. Ltd. in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@Biopharma_Watch](/creator/twitter/Biopharma_Watch) | X    | XXXXX     | X     | XX          |

[View More](/list/creators/$4151t/100)
  
  
### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$4151t/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$4151t/time-series/sentiment.tsv)  
Current Value: XXX%  
Daily Average: XX%  
X Month: XXX% no change  
X Months: XXX% no change  
X Year: XXX% no change  
1-Year High: XXX% on 2024-12-11  
1-Year Low: X% on 2025-03-18  

Most Supportive Themes:
- FDA Approvals and New Product Launches: (40%) Positive news regarding FDA approvals and new product launches is driving social media discussions.
- Market Growth and Expansion: (30%) Discussions indicate expected major growth in specific markets, such as Cutaneous T-cell Lymphoma.
- Partnerships and Collaborations: (30%) Mentions of collaborations with other pharmaceutical companies in treatment development.
  
Most Critical Themes:
- Financial Transactions and Payments: (60%) Significant financial transactions, including payments from Kyowa Kirin to other companies, are being highlighted.
- Drug Development and Approvals: (40%) Specific drugs like KOMZIFTI are being discussed in relation to FDA approval and commercial sales.
  
  
  
### Market Cap: $undefined
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$4151t/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$4151t/time-series/market_cap.tsv)  
Current Value: $undefined  
Daily Average: $XXXXXXXXXXXXXXXXX  
1-Year High: $XXXXXXXXXXXXXXXXX on 2024-12-11  
1-Year Low: $XXXXXXXXXXXXXXXXX on 2025-02-19  

### Top Kyowa Kirin Co. Ltd. Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$KURA 11.03$ -XXXX% 2025-12-08T15:30:00.000Z Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML"  
[X Link](https://x.com/Biopharma_Watch/status/1998418636642599159) [@Biopharma_Watch](/creator/x/Biopharma_Watch) 2025-12-09T15:45Z 1228 followers, XXX engagements


"$KURA #ASH25 XX% (32/37) CRc and XX% (27/37) CR in newly diagnosed NPM1-m AML with XX% (17/25) of CRc responders achieving molecular MRD negativity by central NGS Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff  XX% (31/48) ORR in R/R NPM1-m AML XX% (19/23) ORR in venetoclax-nave  XX% (13/32) ORR in R/R KMT2A-r AML XX% (7/10) ORR in venetoclax-nave"  
[X Link](https://x.com/semodough/status/1998104716065030411) [@semodough](/creator/x/semodough) 2025-12-08T18:57Z 41.9K followers, 4231 engagements


"$KURA 11.96$ XXXX% 2025-12-02T13:02:00.000Z First U.S. Commercial Sale of KOMZIFTI Triggers $XXX Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin"  
[X Link](https://x.com/Biopharma_Watch/status/1996606694898749905) [@Biopharma_Watch](/creator/x/Biopharma_Watch) 2025-12-04T15:45Z 1228 followers, XXX engagements


"Cutaneous T-cell Lymphoma Market Expected to Experience Major Growth by 2032 According to DelveInsight Innate Pharma Galderma R&D Kyowa Kirin Citius Pharma Soligenix 4SC AG #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech"  
[X Link](https://x.com/ABNewswire/status/1996346013792321695) [@ABNewswire](/creator/x/ABNewswire) 2025-12-03T22:29Z 1655 followers, XX engagements